Recurrent Cardiotoxicity Potentiated by the Interaction of Proteasome Inhibitor and Immunomodulatory Therapy for the Treatment of Multiple Myeloma

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.14970
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma

Pharmaceuticals
Molecular MedicinePharmaceutical Science
2014English

Sensitizing Human Multiple Myeloma Cells to the Proteasome Inhibitor Bortezomib by Novel Curcumin Analogs

International Journal of Molecular Medicine
MedicineGenetics
2011English

Novel Strategies in the Treatment of Multiple Myeloma: From Proteasome Inhibitors to Immunotherapy

Journal of Cell Science & Therapy
2010English

Investigating Effects of Proteasome Inhibitor on Multiple Myeloma Cells Using Confocal Raman Microscopy

Sensors
InstrumentationInformation SystemsElectronic EngineeringBiochemistryAnalytical ChemistryMolecular Physics,ElectricalAtomicMedicineOptics
2016English

Proteasome Inhibitor-Induced Modulation Reveals the Spliceosome as a Specific Therapeutic Vulnerability in Multiple Myeloma

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2020English

Novel Drugs for the Treatment of Multiple Myeloma

Haematologica
Hematology
2010English

Bortezomib for the Treatment of Multiple Myeloma Patients

Health Technology Assessment
MedicineHealth Policy
2009English

Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib

Seminars in Hematology
Hematology
2009English

Proteasome Inhibitors Block Ikaros Degradation by Lenalidomide in Multiple Myeloma

Haematologica
Hematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy